Vnitr Lek 2014, 60(3):212-215

Methods of economic analysis of screening programs. Situation in Czech Republic.

Jana Bartáková, Jan Jiskra*
III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

In the process of reducing health budget the question of the effectiveness of investment in population-based screening programs is very actual. Because of the scope, screening is becoming very expensive and burdens healthy people. An essential part of any screening program is careful consideration, registration and monitoring of the results. Here economic analysis are irreplaceable. They enable an objective assessment of the effectiveness of the use of resources and thus become an important basis for decision-making about the allocation of scarce resources for improving the health status of the population. The present text deals with the basic types of economic analysis, including their significance and possibilities when making decisions about recommended screening procedures in the Czech Republic.

Keywords: cost-effectiveness analysis; economic analysis; health care costs; screening

Received: September 22, 2013; Accepted: December 6, 2013; Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartáková J, Jiskra J. Methods of economic analysis of screening programs. Situation in Czech Republic. Vnitr Lek. 2014;60(3):212-215.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Russell LB. Is Prevention Better Than Cure? Brookings Inst Press: Washington, D.C. 1986. ISBN 10: 0815776314 / ISBN 13: 9780815776314.
    2. Doležal T. Význam farmakoekonomického hodnocení. In: Základy farmakoekonomiky pro lékaře, lékárníky a další pracovníky ve zdravotnictví. ČFES: Praha 2007. ISBN 978-80-254-0837-7.
    3. Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press: Oxford (UK) 2005. 3rd ed. ISBN 10: 0198529457 | ISBN-13: 978-0198529453.
    4. Greegor DH. Detection of silent colon cancer in routine examination. CA Cancer J Clin. 1969;19(6): 330-337. Go to original source... Go to PubMed...
    5. Neuhauser D, Lewicki AM. What Do We Gain from the Sixth Stool Guaiac? N Engl J Med. 1975; 293(5): 226-228. Go to original source... Go to PubMed...
    6. Kalager M, Zelen M, Langmark F et al. Effect of Screening Mammography on Breast-Cancer Mortality in Norway. N Engl J Med. 2010; 363(13) :1203-1210. Go to original source... Go to PubMed...
    7. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012; 367(21): 1998-2005. Go to original source... Go to PubMed...
    8. Williams A. The cost-benefit approach. Br Med Bull 1974; 30(3): 252-256. Go to original source... Go to PubMed...
    9. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313(7052): 275-283. Go to original source... Go to PubMed...
    10. Brent RJ. Cost-Benefit Analysis and Health Care Evaluations. Edward Elgar Publishing Ltd: Cheltenham, UK; Northhampton, MA 2004. ISBN 10: 184376508X/ ISBN 13: 9781843765080.
    11. Brown J, Buxton M. The economic perspective. Br Med Bull. 1998;54(4):993-1009. Go to original source... Go to PubMed...
    12. Zerbe RO, Dively D. Benefit-cost analysis in theory and practice: Harper Collins College Publishers: New York 1994. ISBN 0-673-18066-2.
    13. Doležal T, Říhová B, Demlová R et al. Principy farmakoekonomického hodnocení - světové trendy a česká realita. Postgraduální medicína 2011; 13(8): 825-827.
    14. Hájek P. Hranice ochoty platit (willingness to pay) - kam směřujeme v ČR? Farmakoekonomika 2012; 6(1): 7-8.
    15. Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making. 2008; 28(1): 66-89. Go to original source... Go to PubMed...
    16. Scheunemann LP, White DB. The ethics and reality of rationing in medicine. Chest 2011; 140(6): 1625-1632. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.